Drugs / PALTIMATRECTINIB
PALTIMATRECTINIB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05692570 | Sep → Nov 2022 | — | Pyramid Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05238337 | Feb → Mar 2022 | — | Pyramid Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05690932 | Feb → May 2022 | — | Pyramid Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05160389 | Nov 2021 → Jan 2022 | — | Pyramid Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04901806 | Jul 2021 → Jul 2023 | desmoplastic small round cell tumor, primary brain neoplasm | Pyramid Biosciences | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PALTIMATRECTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095076 ↗ |
| Known as | PBI-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04901806 ↗ |
| Known as | PPI-5278 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095076 ↗ |
| Action | Inhibit | “PBI-200 is a TRK inhibitor” NCT05692570 ↗ |
| Modality | Small molecule | — CHEMBL5095076 ↗ |
| Route | Oral | “administered orally” NCT04901806 ↗ |